Overview
Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to regenerate adenosine triphosphate (ATP) from adenosine diphosphate (ADP).
Indication
Phosphocreatine is a naturally occuring substance that is found predominantly in the skeletal muscles of vertebrates. Its primary utility within the body is to serve in the maintanence and recycling of adenosine triphosphate (ATP) for muscular activity like contractions. Given this utility of phosphocreatine to recycle ATP, the most plausible therapeutic potentials for its use involve conditions caused by energy shortage or by increased energy requirements - such as in ischemic stroke and other cerebrovascular diseases. It is important to note however that relatively little clinical research has been done to significantly further the evidence for any such indications, although it is administered intravenously for cardiovascular conditions in some countries. Additionally, because phosphocreatine is not regulated as a controlled substance it is taken as a supplement by some professional athletes as a means to perhaps increase short bursts of muscle strength or energy for professional athletics.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/07/16 | Phase 3 | Recruiting | |||
2022/06/24 | Phase 2 | Recruiting | |||
2017/05/03 | Phase 2 | UNKNOWN | Zhujiang Hospital | ||
2016/05/02 | Phase 3 | Completed | Meshalkin Research Institute of Pathology of Circulation |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Creatine Phosphate Sodium for Injection | 国药准字HJ20140265 | 化学药品 | 注射剂 | 2/19/2025 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20183518 | 化学药品 | 注射剂 | 11/8/2023 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20058621 | 化学药品 | 注射剂 | 7/23/2020 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20054352 | 化学药品 | 注射剂 | 10/16/2020 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20143053 | 化学药品 | 注射剂 | 1/29/2023 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20045399 | 化学药品 | 注射剂 | 7/23/2020 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20203111 | 化学药品 | 注射剂 | 3/24/2020 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20193287 | 化学药品 | 注射剂 | 9/29/2019 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20183477 | 化学药品 | 注射剂 | 11/20/2023 | |
| Creatine Phosphate Sodium for Injection | 国药准字H20203110 | 化学药品 | 注射剂 | 3/24/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.